Multidisciplinary treatment and immunotherapy improved the prognosis of advanced small intestine sarcomatoid carcinoma

Acknowledgements

This study was supported by the National Health Commis- sion Medical and Health Technology Development Research Center, Innov ativ e Drugs Clinical Research Fund ( Grant No. WKZX2023CX090001 ) and the 1.3.5 Project for Disciplines of Ex- cellence, West China Hospital, Sic huan Univ ersity ( Gr ant No. ZYJC21017 ) . We would like to thank the patient for his assistance in providing information and written informed consent. We would also like to thank the pathologists for their support in offering histopathological images.

Author contributions

M.Q.: Conceptualization. B.W.: Original dr aft pr epar ation. All au- thors: supervision and editing of the original paper.

Conflict of interest

None declared.

References

[1] Odze RD, Goldblum JR. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. Philadelphia: Elsevier Health Sciences, 2014;581-96.

[2] Rosli N, Shukor NA. Sarcomatoid carcinoma of small intestine: A case. Chonnam Med J 2021;57:89-90. https://doi.org/10.4068/cmj.2021.57.1.89.

[3] Robey-Cafferty SS, Silva EG, Cleary KR. Anaplastic and sarcomatoid carcinoma of the small intestine: a clinicopathologic study. Hum Pathol 1989;20:858-63. https://doi.org/10.1016/0046-8177(89)90097-X.

[4] Reid-Nicholson M, Idrees M, Perino G et al. Sarcomatoid carcinoma of the small intestine: a case report and review of the literature. Arch Pathol Lab Med 2004;128:918-21.

[5] Ro JY, Chen JL, Lee JS et al. Sarcomatoid carcinoma of the lungImmunohistochemical and ultrastructural studies of 14 cases. Cancer 1992;69:376-86. https://doi.org/10.1002/1097-0142(19920115)69:2%3C376::aid-cncr2820690218%3E3.0.co;2-u.

[6] Duvivier HL, Rothe M, Mangat PK et al. Pembrolizumab in patients with tumors with high tumor mutational burden: Results from the targeted agent and profiling utilization registry study. JCO 2023;41:5140-50. https://doi.org/10.1200/JCO.23.00702.

[7] Friedman CF, Hainsworth JD, Kurzrock R et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discov 2022;12:654-69. https://doi.org/10.1158/2159-8290.CD-21-0450.

[8] Marabelle A, Fakih M, Lopez J et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353-65. https://doi.org/10.1016/S1470-2045(20)30445-9.

[9] Kurra V, Sullivan RJ, Gainor JF et al. Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes. J Clin Oncol 2016;34:6580. https://doi.org/10.1200/JCO.2016.34.15_suppl.6580.